We are live on ! Find out more
XBIT icon

XBiotech

44 hedge funds and large institutions have $13M invested in XBiotech in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

1.67% less ownership

Funds ownership: 11%9.33% (-1.7%)

2% less funds holding

Funds holding: 4544 (-1)

13% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 8

23% less capital invested

Capital invested by funds: $17M → $13M (-$3.94M)

81% less call options, than puts

Call options by funds: $132K | Put options by funds: $708K

Holders
44
Holders Change
-1
Holders Change %
-2.22%
% of All Funds
1%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
12
Reduced
13
Closed
8
Calls
$132K
Puts
$708K
Net Calls
-$576K
Net Calls Change
+$334K
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
51
UBS Group
Switzerland
-$1K -229 Closed
MAM
52
Meeder Asset Management
Ohio
-$1K -177 Closed

XBIT Hedge Fund Activity: Q4 2017 in Review

44 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q4 2017, worth a combined $13M — down 23% from $17M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of XBIT and 7 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 12 added.

The largest buyer was Paloma Partners, opening a new position worth an estimated $166K. The largest seller was BlackRock, cutting an estimated $2.34M.

  • 44 institutional investors held XBiotech (XBIT) as of Q4 2017, down from 45 in Q3 2017.
  • Funds reported $13M of XBiotech stock for Q4 2017, down 23% quarter-over-quarter.
  • 7 funds opened new XBiotech positions in Q4 2017 and 8 closed out, a net change of -1 holder.
  • The largest XBiotech buyer in Q4 2017 was Paloma Partners, an estimated $166K added.
  • The largest XBiotech seller in Q4 2017 was BlackRock, an estimated $2.34M sold.

Based on aggregated 13F filings for Q4 2017.